Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 1, Issue 2, 2004, Pages 90-97

  Fung, Scott K ^a   Lok, Anna S F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Adefovir dipivoxil; Antiviral resistance; Chronic hepatitis B; Lamivudine

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; CLEVUDINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; GENE MUTATION; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; LIVER CIRRHOSIS; LIVER DYSFUNCTION; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; HEPATITIS B; HUMANS; NUCLEOSIDES; NUCLEOTIDES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 20444453279     PISSN: 17434378     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpgasthep0056     Document Type: Review

References (55)

1. Lok A et al. (2001) Management of hepatitis B 2000: summary of a workshop. Gastroenterology 120: 1828-1853
2. Lok ASF and McMahon BJ (2004) Chronic hepatitis B: update of recommendations. Hepatology 39: 857-861
3. EASL Jury (2003). EASL International Consensus Conference on Hepatitis B. J Hepatol 39: S3-S25
4. Severini A et al. (1995) Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 39: 1430-1435
5. Boni C et al. (2001) Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33: 963-971
6. Boni C et al. (2003) Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 39: 595-605
7. Dienstag J et al. (1999) Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341: 1256-1263
8. Lai CL et al. (1998) A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339: 61-68
9. Schalm SW et al. (2000) Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 46: 562-568
10. Guan R et al. (2001) Efficacy and safety of 5 years of lamivudine treatment of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 16 (Suppl 1): A60
11. Jonas M et al. (2002) Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 346: 1706-1713
12. Schiff E, et al. (2003) Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 38: 818-826
13. Dienstag J et al. (2003) Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 37: 748-755
14. Chien RN et al. (2003) Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 38: 1267-1273
15. Song BC et al. (2000) Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32: 803-806
16. Perrillo RP et al. (2002) Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 36: 186-194
17. Tassopoulos N et al. (1999) Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 29: 889-896
18. Hadziyannis S et al. (2000) Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32: 847-851
19. Rizzetto M et al. (2000) Response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol 61: 398-402
20. Papatheodoridis G et al. (2002) Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 36: 219-226
21. Tassopoulos NC et al. (1999) Post lamivudine treatment follow-up of patients with HBeAg-negative chronic hepatitis B [abstract]. J Hepatol 30: 117
22. Fung SK et al. (1999) Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen negative chronic hepatitis B. J Viral Hepal 11: 432-438
23. Liaw YF et al. (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351: 1521-1531
24. Villeneuve JP et al. (2000) Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 31: 207-210
25. Fontana RJ et al. (2002) Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 123: 719-727
26. Locarnini S (2003) Hepatitis B viral resistance: mechanisms and diagnosis. J Hepatol 39: S124-S132
27. Allen MI et al. (1998) Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27: 1670-1677
28. Lok ASF et al. (2003) Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125: 1714-1722
29. Yuen MF et al. (2001) Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34: 785-791
30. Dienstag J et al. (2003) Histological outcome during long-term lamivudine therapy. Gastroenterology 124: 105-117
31. Liaw YF et al. (1999) Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30: 567-572
32. de Man RA et al. (1998) The sequential occurrence of viral mutations in a liver transplant receipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol 29: 669-875
33. Mutimer D et al. (1999) High pretreatment serum hepatitis B virus titer predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 30: 715-721
34. Liaw YF et al. (2002) To continue or not continue lamivudine therapy after the emergence of YMDD mutations [abstract]. Gastroenterology 122: 7
35. Wong V et al. (2002) Is it safe to stop lamivudine after the emergence of YMDD mutants during lamivudine therapy for chronic hepatitis B? [abstract]. J Hepatol 36 (Suppl): A625
36. De Clercq E (1994) Antiviral activity spectrum and target of action of different classes of nucleoside analogues. Nucleic Acids 13: 1271-1295
37. Ono-Nita SK, et al. (1999) Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 103: 1635-1640
38. Marcellin P et al. (2003) Adefovir dipivoxil for the treatment of hepatitis B e Antigen-positive chronic hepatitis B. N Engl J Med 348: 808-816
39. Shiffman M et al. (2004) HBsAg seroconversion in adefovir dipivoxil (ADV) treated chronic hepatitis B (CHB) patients [abstract]. J Hepatol 40: A45
40. Hadziyannis S et al. (2003) Adefovir dipivoxil for the treatment of hepatitis B e-antigen-negative chronic hepatitis B. N Engl J Med 348: 800-807 ;
41. Hadziyannis S, et al. (2004) Three year study of adefovir dipivoxil demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B patients in a long term safety and efficacy study [abstract]. J Hepatol 40: A46
42. Hadziyannis S et al. (2003) Long-term (96 weeks) adefovir dipivoxil in HBeAg-negative chronic hepatitis results in significant virological, biochemical and histological improvement [abstract]. Hepatology 38: 273A
43. Schiff E et al. (2003) Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 38: 1419-1427
44. Perrillo RP et al. (2004) Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 126: 81-90
45. Peters M et al. (2004) Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126: 91-101
46. Westland CE et al. (2003) Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 38: 96-103
47. Angus P et al. (2003) Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125: 292-297
48. Qi X et al. (2004) Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy [abstract]. J Hepatol 40 (Suppl): A57
49. Villeneuve JP et al. (2003) Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 39: 1085-1089
50. Sung JJY et al. (2003) A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B: week 52 analysis [abstract]. J Hepatol 38 (Suppl 2): 25A
51. Lai CL et al. (2002) Entecavir is superior to lamivudine in reducing hepatitis B DNA in patients with chronic hepatitis B infection. Gastroenterology 123: 1831-1838
52. Tenney DJ et al. (2004) Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 48: 3498-3507
53. Marcellin P et al. (2004) A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 40: 140-148
54. Lai CL et al. (2003) Results of a one-year international phase IIB comparative trial of telbivudine, lamivudine, and the combination, in patients with chronic hepatitis B [abstract]. Hepatology 38 (Suppl): 262A
55. van Bommel F et al. (2002) Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 36: 507-508